Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 13/20 | 0.81 |
| ▸ | GAA | P10253 | 13/20 | 0.81 |
| ▸ | SI | P14410 | 13/20 | 0.81 |
| ▸ | MGAM2 | Q2M2H8 | 13/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | GFER | P55789 | 1/20 | 0.72 |
| ▸ | FAAH | O00519 | 1/20 | 0.70 |
| ▸ | GUSB | P08236 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670600 | 0.88 | MGAM (0.78) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL1670602 | 0.88 | MGAM (0.78) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL3463705 | 0.83 | FAAH (1.00) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL28590182 | 0.79 | MGAM (0.80) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL28590184 | 0.79 | MGAM (0.80) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL30279589 | 0.79 | MGAM (0.80) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL17832067 | 0.74 | MEN1 (0.78) | MGAMGAAMEN1KMT2APOLB | |
| SCHEMBL17825554 | 0.74 | MEN1 (0.78) | MGAMGAAMEN1KMT2APOLB | |
| SCHEMBL29712299 | 0.74 | MEN1 (0.78) | MGAMGAAMEN1KMT2APOLB | |
| SCHEMBL17825556 | 0.74 | MEN1 (0.78) | MGAMGAAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | MGAM 4284/4885GAA 479/4885SI 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.